| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ANKRD12_0014900 | Intron-Exon-Intron | chr18:9273968-9275665 | chr18:9273970-9275667 | 1698 nt | 0.4093 |
| hsa_ANKRD12_0015000 | Exon-Exon | chr18:9275522-9282763 | chr18:9275524-9282765 | 144 nt | 0.4028 |
| hsa_ANKRD12_0015100 | Intron-Intron | chr18:9277603-9278509 | chr18:9277605-9278511 | 907 nt | 0.3484 |
| hsa_ANKRD12_0015200 | Exon-Exon | chr18:9282355-9282576 | chr18:9282357-9282578 | 222 nt | 0.2432 |
| hsa_chr18_0229600 | Intergenic-Intergenic | chr18:9284189-9284412 | chr18:9284191-9284414 | 224 nt | 0.3259 |
A study in humans demonstrated that circANKRD12 circANKRD12 was significantly upregulated in the peripheral blood of myocardial infarction patients compared to healthy controls, with RT-qPCR validation showing high diagnostic efficacy as reflected by an area under the curve of 0.7819 in receiver operating characteristic analysis [Li et al. DOI:10.3389/fcvm.2022.810257]. A study in humans demonstrated that the circANKRD12 was identified as a differentially expressed circular RNA in the peripheral blood of myocardial infarction patients and was confirmed in an AC16 cell model [Tian et al. DOI: 10.3390/molecules26041155].